MedTrace Logo

Long-term Neurocognitive and Psychiatric Consequences in Severe COVID-19 Survivors.

NCT05019300 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2021-08-31

No results posted yet for this study

Summary

Long-term neurocognitive and psychiatric consequences of COVID-19 remain mostly unknown to date. It has been reported that coronaviruses cause direct central nervous system infection (Needham et al. 2020). Besides that, new or worsening cognitive impairment commonly occurs and persists in survivors of intensive care unit (ICU) stay (Hosey \& Needham. 2020). The purpose of our study is to search and describe the cognitive and psychiatric long-term consequences of COVID-19 on patients who have been discharged from critical care units. This is an ambidirectional cohort study, that attempts to follow adults discharged from critical Care Units Adults due to COVID-19 up to 12 months after discharge, to evaluate the presence of cognitive impairment, linguistic and phonation function, depression, fatigue, functional gastroenterological symptoms, anxiety, or post traumatic disorder, and performance in activities of daily living and physical response to exercise as well.

Conditions

  • Covid19
  • Neurocognitive Dysfunction

Interventions

BIOLOGICAL

Exposure: COVID-19 severity

COVID-19 severity between 4 to 7 points according the seven-category scale of clinical status reported by Huang et al. (2021) and severe to critical symptomatic levels on spectrum of disease reported by Wu and McGoogan (2020).

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Pontificia Universidad Catolica de Chile

    lead OTHER

Principal Investigators

  • Rafael Medina, PhD · Pontificia Universidad Catolica de Chile

  • Arnoldo Riquelme, PhD · Pontificia Universidad Catolica de Chile

  • Constanza Caneo, MD · Pontificia Universidad Catolica de Chile

  • Carolina Mendez, PhD · Pontificia Universidad Catolica de Chile

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-24
Primary Completion
2021-09-30
Completion
2021-10-31

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05019300 on ClinicalTrials.gov